| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049641366 |
| P356 | DOI | 10.1186/2051-5960-1-11 |
| P932 | PMC publication ID | 4046687 |
| P698 | PubMed publication ID | 24252509 |
| P5875 | ResearchGate publication ID | 257885167 |
| P50 | author | Glenda Halliday | Q45304807 |
| Louise Cottle | Q104746923 | ||
| P2093 | author name string | Karen E Murphy | |
| Antony A Cooper | |||
| Amanda M Gysbers | |||
| P2860 | cites work | Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism | Q24301367 |
| Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity | Q24337043 | ||
| Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity | Q27934988 | ||
| Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove | Q28115428 | ||
| ATP13A2 regulates mitochondrial bioenergetics through macroautophagy | Q28116275 | ||
| Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase | Q28116395 | ||
| PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity | Q28117134 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| The role of the Parkinson's disease gene PARK9 in essential cellular pathways and the manganese homeostasis network in yeast | Q34212205 | ||
| Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity | Q34636872 | ||
| Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. | Q36066469 | ||
| Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria | Q37631959 | ||
| Lysosomal dysfunction in neurodegeneration: the role of ATP13A2/PARK9. | Q42321201 | ||
| Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease | Q51592951 | ||
| Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type | Q52044615 | ||
| Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease | Q73789480 | ||
| P921 | main subject | brain tissue | Q11850260 |
| P304 | page(s) | 11 | |
| P577 | publication date | 2013-05-09 | |
| P1433 | published in | Acta Neuropathologica Communications | Q27724912 |
| P1476 | title | ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies | |
| P478 | volume | 1 |
| Q39193441 | Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson’s disease |
| Q93363369 | Apolipoprotein D Upregulation in Alzheimer's Disease but Not Frontotemporal Dementia |
| Q30383670 | Atp13a2 expression in the periaqueductal gray is decreased in the Pink1 -/- rat model of Parkinson disease. |
| Q64763405 | Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery |
| Q45923792 | Biometal Dyshomeostasis and Toxic Metal Accumulations in the Development of Alzheimer's Disease. |
| Q33364337 | Copy number variability in Parkinson's disease: assembling the puzzle through a systems biology approach |
| Q38225786 | Defective autophagy in Parkinson's disease: lessons from genetics |
| Q89596060 | Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function |
| Q26764724 | Emerging preclinical pharmacological targets for Parkinson's disease |
| Q94586186 | Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson's disease pathogenesis |
| Q64073224 | Glial phagocytic clearance in Parkinson's disease |
| Q28588670 | LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance |
| Q28084859 | Legal but lethal: functional protein aggregation at the verge of toxicity |
| Q92086130 | Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson's disease |
| Q41574315 | Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease |
| Q39247520 | Mechanisms of Gene-Environment Interactions in Parkinson's Disease |
| Q34100399 | Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review |
| Q52559939 | Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process. |
| Q27932080 | Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes |
| Q53387936 | Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression |
| Q24324577 | Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease |
| Q28118364 | Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease |
| Q36069844 | Splicing: is there an alternative contribution to Parkinson's disease? |
| Q90073258 | Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts |
| Q38434200 | The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms |
| Q38765856 | Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. |
Search more.